GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2011

Hanmi Licenses Kinex’ Phase II Anticancer Candidate in Select Asian Countries

  • Korean firm Hanmi Pharmaceutical negotiated exclusive rights to Kinex Pharmaceuticals’ lead clinical-stage anticancer candidate, KX01 (KX2-391), for all oncology indications in selected Asian territories including China and Korea but excluding Japan. KX01 is currently in Phase II trials for the treatment of prostate cancer. Phase II studies in leukemia, ovarian cancer, and triple-negative breast cancer are expected to start during 2011. 

    Under terms of the deal, Kinex will receive an up-front payment, milestones, and sales royalties. Hanmi will shoulder all development responsibilities and associated costs in its designated territories and will work with Kinex on global Phase III trials. 

    KX01 has been developed by Kinex using its Mimetica™ and Opal™ (optimized photo-affinity labeling) platforms. Mimetica is a a technology for designing small molecule kinase inhibitors that bind in the substrate pocket. Opal has been developed to identify intracellular targets that bind to small molecule drugs and provide information on the mechanism of action of drug candidates. Kinex claims KX01 has a dual mechanism of action involving Src kinase signalling inhibition and pretubulin inhibition. A second src/pretubulin inhibitor, KX02, is expected to start in Phase I trials during 2011.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »